PRESS RELEASE published on 10/18/2023 at 14:30, 11 months 10 days ago Napo Pharmaceuticals to Exhibit at the October 25-28 Annual Association of Nurses in AIDS Care (ANAC) Conference for Mytesi, the Company’s FDA-Approved Prescription Drug
PRESS RELEASE published on 10/12/2023 at 14:30, 11 months 16 days ago Jaguar Health to Present October 17 at the Lytham Partners Fall 2023 Investor Conference and October 18 at the BIO Investor Forum
PRESS RELEASE published on 10/10/2023 at 14:30, 11 months 18 days ago Jaguar Animal Health Exhibiting at October 12-14 VCS Annual Conference for Canalevia-CA1, the Company's FDA Conditionally Approved Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs
PRESS RELEASE published on 09/28/2023 at 14:30, 1 year ago Jaguar Health to Present October 3 at LD Micro's Main Event Investor Conference, and on October 5 at the Global Capital Network Investor Conference
PRESS RELEASE published on 09/27/2023 at 14:30, 1 year ago Jaguar Health Launches TikTok and Instagram Contest to Raise Awareness About Common Yet Barely Addressed Health Condition: Surprise Diarrhea
PRESS RELEASE published on 09/26/2023 at 14:30, 1 year ago Napo Pharmaceuticals Supports Groundbreaking Study on Quality of Life for Cancer Patients and Survivors
PRESS RELEASE published on 09/21/2023 at 13:30, 1 year ago Jaguar Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences for Research in Treating ADHD
PRESS RELEASE published on 09/14/2023 at 14:30, 1 year ago Jaguar Health Shares Presentation Replay Link from September 11-13, 2023 H.C. Wainwright Annual Global Investment Conference
PRESS RELEASE published on 09/13/2023 at 14:30, 1 year ago Patent Issued in Japan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
PRESS RELEASE published on 09/12/2023 at 14:30, 1 year ago Napo Pharmaceuticals, a Jaguar Health Family Company, Submits Funding Application to National Institute of Allergy and Infectious Diseases for Development of NP-300 Drug Candidate for Cholera-Related Diarrhea
Published on 09/28/2024 at 02:06, 23 hours 11 minutes ago Global Education Communities Corp. Reports Second Tranche Closing of Non-Brokered Private Placement
Published on 09/28/2024 at 02:00, 23 hours 17 minutes ago Quantum Biopharma Provides Corporate Update
Published on 09/28/2024 at 02:00, 23 hours 17 minutes ago bettermoo(d)’s Moodrink(TM) Featured in Banners of Well-Known Canadian Retailers
Published on 09/28/2024 at 00:10, 1 day 1 hour ago LQWD Technologies Announces Non-Brokered Private Placement Update
Published on 09/28/2024 at 14:01, 11 hours 16 minutes ago Turkiye Garanti Bankasi A.S.: Explanation on Subordinated Debt Securities to Qualified Investors
Published on 09/27/2024 at 22:30, 1 day 2 hours ago DREAM Pivotal Study Data Presented at the International Surgical Sleep Society 2024 Educational Update
Published on 09/27/2024 at 21:56, 1 day 3 hours ago EQS-Adhoc: FDA grants approval for Stelara® Biosimilar FYB202/OtulfiTM (ustekinumab-aauz)
Published on 09/27/2024 at 18:50, 1 day 6 hours ago PETROFAC ANNOUNCES IN-PRINCIPLE AGREEMENT ON FINANCIAL RESTRUCTURE
Published on 09/27/2024 at 18:40, 1 day 6 hours ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 09/27/2024 at 17:45, 1 day 7 hours ago NFL BIOSCIENCES: 2024 FIRST-HALF BUSINESS AND EARNINGS UPDATE
Published on 09/26/2024 at 18:00, 2 days 7 hours ago GUILLEMOT CORPORATION: Availability of the interim financial report to June 30, 2024
Published on 09/26/2024 at 18:00, 2 days 7 hours ago GUILLEMOT CORPORATION: 2024 CONSOLIDATED INTERIM RESULTS
Published on 09/26/2024 at 17:47, 2 days 7 hours ago imerys-26-September-2024-information-share-capital-and-voting-rights-as-of-31-August-2024